Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - IntelGenx Technologies Corp. | exhibit99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
the Securities and Exchange Act of 1934
Date of Report (Date of earliest event reported): August 22, 2016
IntelGenx Technologies
Corp.
(Exact name of registrant as specified in its
charter)
| Delaware | 000-31187 | 87-0638336 |
| (State or other jurisdiction of incorporation) | (Commission File No.) | (IRS Employer ID) |
6420 Abrams, Ville Saint Laurent, Quebec, H4S 1Y2 Canada
(Address of principal executive offices and Zip Code)
(514) 331-7440
(Registrant's telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| |_| |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
| |
| |_| |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
| |
| |_| |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
| |
| |_| |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events - News Release
IntelGenx Announces Successful Clinical Study for
Montelukast for the Treatment of
Degenerative Diseases of the
Brain
| Exhibit | Description |
| 99.1 | Press Release |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INTELGENX TECHNOLOGIES CORP. | |
| Dated: August 22, 2016 | By: /s/ Horst Zerbe |
| Horst G. Zerbe | |
| President and Chief Executive Officer |